U.S. markets closed

Foghorn Therapeutics Inc. (FHTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.17+0.16 (+2.28%)
At close: 04:00PM EST
7.17 0.00 (0.00%)
After hours: 04:01PM EST

Foghorn Therapeutics Inc.

500 Technology Square
Suite 700
Cambridge, MA 02139
United States
617 586 3100

Full Time Employees119

Key Executives

NameTitlePayExercisedYear Born
Mr. Adrian H. B. GottschalkPres, CEO & Director945kN/A1976
Dr. Allan Reine M.D.Chief Financial Officer665.6kN/A1975
Dr. Samuel Agresta M.D., M.P.H.Chief Medical Officer685.6kN/A1973
Dr. Gerald R. Crabtree M.d.Founder & Member of Scientific Advisory BoardN/AN/AN/A
Dr. Steven F. Bellon Ph.D.Chief Scientific OfficerN/AN/A1965
Mr. Ben StrainVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Michael J. LaCasciaChief Legal OfficerN/AN/A1965
Mr. Saurabh Sewak Ph.D.VP of Corp. Devel.N/AN/AN/A
Mr. Carlos CostaChief People OfficerN/AN/AN/A
Ms. Fanny CavalieChief Strategy & Bus. Operations OfficerN/AN/A1978
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Foghorn Therapeutics Inc.’s ISS Governance QualityScore as of November 28, 2022 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.